Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Shandong XINDE Technology Co. Ltd. is a private company headquartered in Weifang, China, that manufactures pharmaceutical products.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Qingdao Xinde Pharmaceutical Co., Ltd., established on 2002-04-24, Business scope includes sales of veterinary biological products,research and development(According to the approval issued by the animal husbandry and veterinary department<Veterinary drug business license>Carry out business activities),Sales:veterinary medicine(According to the approval issued by the animal husbandry and veterinary department<Veterinary drug business license>Carry out business activities),Feed additives,feed,Farming Equipment,pet food,Toy,crafts,Import and export(Projects prohibited by laws and administrative regulations shall not be operated,Operations after permits for projects restricted by laws and administrative regulations),Farming technical service,technical consulting,Animal Health Technical Services,technical consulting,Realtor.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Fuso Pharmaceutical Industries, Ltd. engages in the manufacture and sale of ethical pharmaceutical and medical equipment. It operates through the Pharmaceuticals and Real Estate divisions. The Pharmaceuticals division deals with the manufacture and sale of pharmaceutical products which mainly focus on prescription drugs, infusions, and artificial kidney dialysis solutions. The Real Estate division handles leasing of real estate properties. The company was founded on March 25, 1937 and is headquartered in Osaka, Japan.

Denka Corp., part of Denka Co., Ltd., is an American company located in New York, NY. The firm manufactures and distributes chemical products.

Researches on gen thereapy.

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

Zhaoqing Dahuanong Biopharmaceutical Co., Ltd., established on 2002-07-22, The business scope includes the production of veterinary vaccines;sales of veterinary drugs;Technical Services;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).The branch produces inactivated embryotoxin vaccines;Sales of veterinary biological products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Huanong (Zhaoqing) Bio-Industry Technology Research Institute Co., Ltd., established on 2017-01-26, The scope of business includes the provision of biotechnology,Marine fish farming,Project R&D services in food safety and other related technical fields,Transformation of scientific and technological achievements,Project development and introduction,Provide technical and consulting services for related projects and industries;Veterinary Services;Agricultural Services;design,processing(pilot test),Sales:Biotechnology Related Products,and provide related services;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Momotaro-Gene Inc. engages in the development of molecular targeting drugs for cancer treatment. It also acting as a bridge between promising technology seeds in life science and real drug market in order to effectively bringing the research outcome to the citizens globally. The company was founded on August 17, 2007 and is headquartered in Okayama, Japan.

Jiangsu Qitian Gene Biotechnology Co., Ltd., established on 2012-08-29, Business scope includes genetic biological products,Nucleic Acid Amplification Reagents,Nucleic acid detection reagent,Veterinary biological products,Technology research and development of nucleic acid amplification detection instruments,manufacture,Sales;Detection kit(Does not contain drugs,dangerous goods),Research and development of a class of medical devices,Sales;Animal and plant disease control;computer software development,Technical Services;Socio-Economic Information Consulting Services(Does not include investment advice);Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Veterinary drug production;Veterinary drug business;Class III medical device business;Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Guangzhou Enbao Biomedical Technology Co., Ltd., established on 2012-04-25, Business scope includes engineering and technology research and experimental development;Natural science research and experimental development;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;Manufacturing of bio-based materials;Sales of bio-based materials;

Chongqing Yongjian Biotechnology Co., Ltd., established on 2001-05-17, Business scope includes licensed projects:research and development,Production,sale veterinary:Biological product,Biochemicals(Does not contain dangerous goods),Terminally sterilized small volume injection(Contains Chinese herbal extracts),powder injection,powder,Powder,Premix,Terminally Sterilized Bulk Non-intravenous Injectables(Contains Chinese herbal extracts),oral solution,Yolk antibody,Animal Clinic(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Research and development of high-tech products,Achievement transfer;Goods import and export business,Technology import and export business(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Nichi-Iko Pharmaceutical Co., Ltd. is the largest generic drug manufacturer in Japan by sales. In FY2014, it became the first Japanese generic medicine manufacturer to reach JPY100 billion in annual sales, and consolidated net sales in the fiscal year ended March 31, 2016 reached JPY143.5 billion. Since its establishment in 1965, Nichi-Iko has earned a reputation for operating at the forefront of quality assurance with premium quality generic pharmaceuticals. It has grown market share with an extensive lineup of more than 1,000 commercialized products — the largest number among domestic pharmaceutical manufacturers — as well as strong relationships with wholesalers. Nichi-Iko’s development has been enhanced by six acquisitions and nine business alliances since the appointment of current President & CEO Yuichi Tamura in 2000. Nichi-Iko employs 1,142 people and operates seven production sites, one R&D facility, and four distribution centers throughout Japan. In Obelisk, its seventh Medium-term Business Plan for the three fiscal years from April 2016 through March 2019, Nichi-Iko aims to become a global Top 10 generics company, underpinned by three core strategies: Power of Expansion, Power of Production, and Power of Development.

Xixian New District Yuguo Microcode Biotechnology Co., Ltd., established on 2017-03-07, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Sales of Class I Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Instrument Manufacturing;Instrument sales;Manufacturing of experimental analysis instruments;Mechanical equipment research and development;Machinery sales;Manufacturing of computer software, hardware and peripheral equipment;electronics sales;Manufacturing of office equipment consumables;Sales of office equipment consumables;internet data service;software development;Data processing and storage support services;Import and export;Technology Import and Export;Consulting and planning service;Information Consulting Service(Not including licensing information consulting services);market survey(Does not include foreign investigations);Conference and Exhibition Services;business management;Socioeconomic Advisory Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:medical service;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

QYH Biotech Co., Ltd. engages in the research, development, and production of vaccines for major animal diseases such as highly pathogenic avian influenza and highly pathogenic swine blue ear disease. The company was founded on July 1, 2004 and is headquartered in Beijing.